Press release - 20/01/2026 Exciva raises €51 million ($59m) in Series B funding round co-led by Gimv and EQT Exciva GmbH, a biopharmaceutical company developing novel therapeutic compounds for the treatment of neuropsychiatric conditions, today announces the closing of a €51 million ($59m) Series B financing round. Gimv and EQT Life Sciences co-led the round. Additional participants included new investors Fountain Healthcare Partners, LifeArc Ventures, Carma Fund and Modi Ventures, as well as existing investors Andera Partners and LBBW.https://www.gesundheitsindustrie-bw.de/en/article/press-release/exciva-raises-euro-51-million-dollar-59m-series-b-funding-round-co-led-gimv-and-eqt
Event - 05/03/2026 ELRIG.de Forum 2026 Darmstadt, Forum https://www.gesundheitsindustrie-bw.de/en/event/elrigde-forum-2026
Press release - 20/01/2026 Spatial organisation of genetic material influences heart disease In a joint study conducted by the DZHK sites in Heidelberg, Munich and Göttingen, researchers are deciphering how the spatial organisation of the genome in the heart determines genetic disease risks.https://www.gesundheitsindustrie-bw.de/en/article/press-release/spatial-organisation-genetic-material-influences-heart-disease
